Press release
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral
About this update from Natera, Inc.
[{"type":"text","content":"\nStudies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera\n\n\nBreast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial\n\n\nSignatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay\n\n\nGI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes \n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL.\n\nTogether with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera’s leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment.\n\n“The depth and breadth of Natera’s research at ASCO is our most significant to date, with multiple impactful datasets in several histologies,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. “The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed.”\n\nHighlights include:\n\n\nDARE Clinical Trial: Oral Presentation\n\n\nDARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of “treatment on molecular recurrence” (TOMR). Patients who were Signatera-positive and imaging-negative were rand...